Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Lionetti R, Calvaruso V, Piccolo P, Mancusi RL, Mazzarelli C, Fagiuoli S, Montalbano M, Lenci I, Carrai P, Guaraldi G, Visco-Comandini U, Milana M, Biolato M, Loiacono L, Valente G, Craxì A, Angelico M, D'offizi G. Lionetti R, et al. Among authors: biolato m. Clin Transplant. 2018 Feb;32(2). doi: 10.1111/ctr.13165. Epub 2017 Dec 18. Clin Transplant. 2018. PMID: 29193356
Fib-4 score is able to predict intra-hospital mortality in 4 different SARS-COV2 waves.
Miele L, Dajko M, Savino MC, Capocchiano ND, Calvez V, Liguori A, Masciocchi C, Vetrone L, Mignini I, Schepis T, Marrone G, Biolato M, Cesario A, Patarnello S, Damiani A, Grieco A, Valentini V, Gasbarrini A; Gemelli against COVID Group. Miele L, et al. Among authors: biolato m. Intern Emerg Med. 2023 Aug;18(5):1415-1427. doi: 10.1007/s11739-023-03310-y. Epub 2023 Jul 25. Intern Emerg Med. 2023. PMID: 37491564 Free PMC article.
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.
Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Di Maio VC, et al. J Antimicrob Chemother. 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17. J Antimicrob Chemother. 2016. PMID: 26679249
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Di Maio VC, et al. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20. Liver Int. 2017. PMID: 28105744
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, Lionetti R, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Fagiuoli S, Belli L, Verucchi G, Puoti M, Craxì A. Calvaruso V, et al. Among authors: biolato m. Sci Rep. 2019 Jan 24;9(1):585. doi: 10.1038/s41598-018-36734-0. Sci Rep. 2019. PMID: 30679515 Free PMC article.
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Miele L, Giorgio V, Liguori A, Petta S, Pastorino R, Arzani D, Alberelli MA, Cefalo C, Marrone G, Biolato M, Rapaccini G, Boccia S, Gasbarrini A, Craxì A, Grieco A. Miele L, et al. Among authors: biolato m. Nutr Metab Cardiovasc Dis. 2020 Oct 30;30(11):2103-2110. doi: 10.1016/j.numecd.2020.06.013. Epub 2020 Jun 27. Nutr Metab Cardiovasc Dis. 2020. PMID: 32807638
Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation.
Lai Q, Magistri P, Lionetti R, Avolio AW, Lenci I, Giannelli V, Pecchi A, Ferri F, Marrone G, Angelico M, Milana M, Schinniná V, Menozzi R, Di Martino M, Grieco A, Manzia TM, Tisone G, Agnes S, Rossi M, Di Benedetto F, Ettorre GM; Sarco-Model Study Group. Lai Q, et al. Liver Int. 2021 Jul;41(7):1629-1640. doi: 10.1111/liv.14889. Epub 2021 Apr 22. Liver Int. 2021. PMID: 33793054
69 results